U.S. Senators Reach Agreement to Cap Insulin Prices
- Insulin Price Cap: A bipartisan group of U.S. senators has reached an agreement to cap insulin prices at $35 per month, aiming to alleviate the financial burden for nearly 30 million Americans diagnosed with diabetes, highlighting a commitment to improving public health.
- Legislative Progress: The proposal, led by Jeanne Shaheen and Susan Collins, requires support from Senate Majority Leader John Thune and President Trump, indicating the political significance and urgency of the bill in addressing healthcare costs.
- Expanded Coverage: Initially focused on insured patients, the bill now includes a pilot program allowing uninsured individuals in 10 states to access insulin at capped prices, reflecting a commitment to supporting vulnerable populations.
- Positive Market Reaction: Following the announcement, shares of major insulin producers rose in pre-market trading, with Sanofi up 2% and Eli Lilly and Novo Nordisk each gaining around 0.5%, indicating market optimism regarding the potential impact of the legislation.
Trade with 70% Backtested Accuracy
Analyst Views on LLY
About LLY
About the author


- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.

New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.

Safety Profile Consistency: The safety profile of the product remains consistent, indicating reliability in its performance.
Lack of New Safety Signals: There have been no new safety signals reported in the first year of monitoring, suggesting ongoing safety assurance.

- Durable Disease Control: Eli Lilly has achieved four years of effective control over a specific disease, demonstrating the durability of their treatment approach.
- Focus on Dermatology: The advancements are particularly relevant in the field of dermatology, highlighting the company's commitment to addressing skin-related health issues.

Treatment Duration: Patients with moderate-to-severe atopic dermatitis can receive up to four years of effective disease control.
Disease Management: The treatment aims to provide durable control of the condition, improving the quality of life for affected individuals.
- Efficacy Durability: In the ADlong Phase 3b study, nearly all patients treated with EBGLYSS achieved significant skin improvement (EASI-75) over four years, with 75% reaching near-complete skin clearance (EASI-90), indicating a transformative impact on the quality of life for eczema patients.
- Itch Relief: 78% of patients experienced significant itch relief (Pruritus NRS≤4) during treatment, which is crucial for enhancing daily living and mental health, demonstrating EBGLYSS's effectiveness in alleviating eczema symptoms.
- Steroid-Free Treatment: 80% of patients achieved results without the need for topical corticosteroids while on EBGLYSS, indicating the drug's ability to provide durable outcomes and reduce reliance on traditional therapies, thereby reshaping the treatment paradigm for eczema.
- Safety Profile: The safety of EBGLYSS in the first year of the ADlong study was consistent with known safety profiles, with no new safety signals observed, and the majority of adverse events were mild or moderate, reinforcing its potential as a first-line biologic treatment.






